Z4152
ザフィルルカスト
≥98% (HPLC), CysLT1 receptor antagonist, solid
別名:
N-[3-[[2-メトキシ-4-[[[(2-メチルフェニル)スルホニル]アミノ]カルボニル]フェニル]メチル]-1-メチル-1H-インドール-5-イル]カルバミン酸シクロペンチルエステル
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C31H33N3O6S
CAS番号:
分子量:
575.68
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
製品名
ザフィルルカスト, ≥98% (HPLC)
SMILES string
COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)OC4CCCC4)cc23)C(=O)NS(=O)(=O)c5ccccc5C
InChI key
YEEZWCHGZNKEEK-UHFFFAOYSA-N
InChI
1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
assay
≥98% (HPLC)
form
solid
solubility
DMSO: ≥28 mg/mL
originator
AstraZeneca
storage temp.
room temp
Quality Level
Gene Information
human ... CYSLTR1(10800)
関連するカテゴリー
Application
Zafirlukast has been used to stimulate pancreatic β cell line (MIN6) and pancreatic islets for insulin secretion assay. It may be used as an adenosine triphosphate-binding cassette transporter (ABCG2) inhibitor in MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cytotoxicity assay in human embryonic kidney cells (HEK293) and in Kirby-Bauer disc diffusion assays, bactericidal activity and minimal inhibitory concentration (mIC) assay against M. smegmatis
Biochem/physiol Actions
ザフィルルカストはCysLT1に強力に作用するサブタイプ特異的なアンタゴニストであり、抗喘息薬です。
ザフィルルカストは、システイニルロイコトリエン1型受容体(CysLT1)に強力に作用するサブタイプ特異的なアンタゴニストであり、抗喘息薬です。CysLT1は、ヒト気管支喘息の重要なメディエーターであるシステイニルロイコトリエンLTC4、LTD4やLTE4に対する2種類の受容体のうちのひとつであり、ザフィルルカストはCysLT1に対して1000倍以上の選択性を有しています。
Zafirlukast plays a key role in alleviating mucus and airway constriction in asthma based inflammatory response. It regulates pancreatic β cells for the secretion of insulin and this functionality is interlinked to the calcium based phosphorylation of the Ca2+/calmodulin-dependent protein kinase II (CaMKII) and protein kinase B (AKT). Zafirlukast has inhibitory potential on ATP-binding cassette (ABC) transporters and reverses the multidrug resistance function of ATP-binding cassette super-family G member 2 (ABCG2). Zafirlukast inhibits mycobacterial nucleoid-associated protein Lsr2 and halts the growth of Mycobacteria.
Features and Benefits
This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 4
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Z4152-VAR: + Z4152-10MG: + Z4152-50MG: + Z4152-BULK:
jan
F Wunder et al.
British journal of pharmacology, 160(2), 399-409 (2010-04-29)
Cysteinyl leukotrienes (CysLTs) have been implicated in the pathophysiology of inflammatory and cardiovascular disorders. Their actions are mediated by CysLT(1) and CysLT(2) receptors. Here we report the discovery of 3-({[(1S,3S)-3-carboxycyclohexyl]amino}carbonyl)-4-(3-{4-[4-(cyclo-hexyloxy)butoxy]phenyl}propoxy) benzoic acid (HAMI3379), the first potent and selective CysLT(2) receptor
Lucile Pinault et al.
Antimicrobial agents and chemotherapy, 57(5), 2134-2140 (2013-02-27)
The mycobacterial nucleoid-associated protein Lsr2 is a DNA-bridging protein that plays a role in condensation and structural organization of the genome and acts as a global repressor of gene transcription. Here we describe experiments demonstrating that zafirlukast inhibits the complexation
P N Richard Dekhuijzen et al.
Clinical pharmacokinetics, 41(2), 105-114 (2002-03-13)
Zafirlukast is a cysteinyl leukotriene type 1 receptor antagonist that causes bronchodilation and has anti-inflammatory properties. Clinical efficacy has been demonstrated when using oral doses of 20 to 40 mg twice daily. The pharmacokinetics of zafirlukast are best described by
Zafirlukast promotes insulin secretion by increasing calcium influx through L-type calcium channels.
Hyeon-Jeong Hwang et al.
Journal of cellular physiology, 233(11), 8701-8710 (2018-05-26)
The zafirlukast has been reported to be anti-inflammatory and widely used to alleviate the symptoms of asthma. However, its influence on insulin secretion in pancreatic β-cells has not been investigated. Herein, we examined the effects of zafirlukast on insulin secretion
James Mann et al.
Molecular pharmaceutics, 14(12), 4192-4201 (2017-07-25)
Dissolution testing with biorelevant media has become widespread in the pharmaceutical industry as a means of better understanding how drugs and formulations behave in the gastrointestinal tract. Until now, however, there have been few attempts to gauge the reproducibility of
資料
Discover Bioactive Small Molecules for Lipid Signaling Research
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）